2016 - 2020

  • TLC is listed on the Nasdaq Global Market (ticker: TLC)
  • TLC initiates EXCELLENCE Phase III trial of TLC599 in knee osteoarthritis pain
  • Phase II trial of TLC590 in bunionectomy successfully completed
  • TLC ranks Top 5%in Corporate Governance Evaluations six years running
  • TLC178 is designated by the US FDA as an orphan drug for the treatment of soft tissue sarcoma and a rare pediatric disease in the treatment of rhabdomyosarcoma.

2011 - 2015

  • TLC receives a top 5% ranking in Corporate Governance Evaluation among all TPEx-listed companies
  • TLC opens subsidiary offices in Australia, Hong Kong, Shanghai and Japan
  • Ampholipad™ is approved and launched in Taiwan
  • TLC388 is accepted into the Green Path accelerated development pathway by the CFDA
  • TLC is listed on the Taipei Exchange (TWO: 4152)

2006 - 2010

  • TLC388 obtains orphan drug designation for development in hepatocellular carcinoma (HCC) in both Europe and the United States
  • TLC establishes subsidiary offices in Leiden, the Netherlands

2001 - 2005

  • TLC establishes subsidiary offices in San Francisco, CA
  • TLC headquarter established in Nangang Software Park, Taipei, Taiwan
  • Lipo-Dox is approved for treatment of breast cancer, ovarian caner, AIDS-related Kaposi's sarcoma and multiple myeloma

1997 - 2000

  • TLC is founded and begins development of Lipo-Dox